Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAPS-18 is a synthetic antimicrobial peptide (AMP) developed for the adjunct treatment of periodontitis. It is typically administered as a 0.85% subgingival gel (marketed under the brand name Ace Helper) following mechanical debridement, such as scaling and root planing. The peptide functions by targeting and disrupting the cell membranes of periodontal pathogens, which helps to reduce the subgingival microbial load and facilitate the transition from a dysbiotic to a symbiotic microbial community. Clinical research, including pilot studies conducted at the University of Malaya, has evaluated its efficacy in improving clinical periodontal parameters like pocket depth and clinical attachment levels in patients with Stage III periodontitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TAPS-18.